Lexapro
ApprovedSmall molecule
Lexapro is one of 172 small molecule programs targeting Dysthymic Disorder. It is currently in Approved.
7
Indications
11
Total Trials
1
Active Trials
171
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Lexapro
SShirley Ryan AbilityLab
Approved
Veramyst
GSKPreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Panic Disorder1 trial
Spinal Cord Injury1 trial
Anxiety1 trial
Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
Completed·—·N/A·NCT02516332·128 enrolled
6 more indications
Depression1 trial
Combination Lexapro and Massage for Treatment of Depression in Older Adults
Terminated·—·N/A·NCT00643162·17 enrolled
Schizophrenia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lexapro. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SShirley Ryan AbilityLab